Literature DB >> 12861380

Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation.

S M Houten1, J Frenkel, H R Waterham.   

Abstract

Mevalonate kinase (MK) is an essential enzyme in the isoprenoid biosynthesis pathway which produces numerous biomolecules (isoprenoids) involved in a variety of cellular processes. The indispensability of MK and isoprenoid biosynthesis for human health is demonstrated by the identification of its deficiency as the biochemical and molecular cause of the inherited autoinflammatory disorders mevalonic aciduria and hyperimmunoglobulinemia D and periodic fever syndrome. Since the discovery of the genetic defect, considerable progress has been made in understanding the molecular, biochemical and immunological basis of MK deficiency. Important questions such as which specific protein(s) and/or signaling pathway(s) are affected, however, remain unanswered. Resolving the complete pathophysiology of this disorder is a major challenge, but eventually will give insight into the in vivo role of MK and isoprenoid biosynthesis in inflammation and fever. This may open novel options for antiinflammatory therapies in general. Here, we give a general introduction on isoprenoid biosynthesis, the regulation thereof and deficiencies therein. We review the molecular, biochemical and immunological aspects of MK deficiency and discuss the relations between isoprenoid biosynthesis and inflammation. Finally, we compare MK deficiency with other autoinflammatory syndromes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861380     DOI: 10.1007/s00018-003-2296-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  23 in total

Review 1.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 2.  New insights into the enigma of immunoglobulin D.

Authors:  Kang Chen; Andrea Cerutti
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

3.  Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.

Authors:  Marc-Alexander L T Parent; David A Hottman; Shaowu Cheng; Wei Zhang; Lori L McMahon; Li-Lian Yuan; Ling Li
Journal:  Cell Mol Neurobiol       Date:  2014-04-01       Impact factor: 5.046

4.  Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency.

Authors:  Annalisa Marcuzzi; Giuliana Decorti; Alessandra Pontillo; Alessandro Ventura; Alberto Tommasini
Journal:  Inflamm Res       Date:  2010-02-21       Impact factor: 4.575

Review 5.  Recurrent febrile syndromes: what a rheumatologist needs to know.

Authors:  Hal M Hoffman; Anna Simon
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

6.  A patient with hyper-IgD syndrome responding to anti-TNF treatment.

Authors:  Erkan Demirkaya; M Kazim Caglar; Hans R Waterham; Rezan Topaloglu; Seza Ozen
Journal:  Clin Rheumatol       Date:  2006-12-15       Impact factor: 2.980

7.  Dietary supplementation with geranylgeraniol suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats.

Authors:  Puspo E Giriwono; Hitoshi Shirakawa; Yusuke Ohsaki; Shuichi Hata; Hiroki Kuriyama; Shoko Sato; Tomoko Goto; Michio Komai
Journal:  Eur J Nutr       Date:  2012-07-31       Impact factor: 5.614

8.  Nummular keratopathy in a patient with Hyper-IgD Syndrome.

Authors:  Courtney L Kraus; Susan M Culican
Journal:  Pediatr Rheumatol Online J       Date:  2009-08-05       Impact factor: 3.054

9.  Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency.

Authors:  L Henneman; M S Schneiders; M Turkenburg; H R Waterham
Journal:  J Inherit Metab Dis       Date:  2010-09-03       Impact factor: 4.982

10.  Developments in the scientific and clinical understanding of autoinflammatory disorders.

Authors:  Helen J Lachmann; Philip N Hawkins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.